This article was originally published in The Gray Sheet
Executive SummaryAnnounces on Feb. 17 plans to repurchase up to 500,000 shares of its common stock "in the open market from time to time." The company cited the low price of the stock as a reason for the repurchase program. The Feb. 16 closing price of the stock was $17.50 per share. Collagen says it has no specific plans for the shares that may be repurchased.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.